Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as GLK-321 low dose BID
GLK-321 low dose · 1 trial · 1 indication
Percentage of study eyes that had eyelash collarettes due to Demodex blepharitis at the onset of treatment who demonstrate absence of collarettes after 6 weeks of treatment
| Arm | Type | Description |
|---|---|---|
| GLK-321 low dose BID | EXPERIMENTAL | Low dose of GLK-321 administered twice daily (BID) to both eyes |
| GLK-321 mid dose BID | EXPERIMENTAL | Mid dose of GLK-321 administered twice daily (BID) to both eyes |
| GLK-321 high dose BID | EXPERIMENTAL | High dose of GLK-321 administered twice daily (BID) to both eyes |
| GLK-321 high dose QD | EXPERIMENTAL | High dose of GLK-321 administered once daily (QD) to both eyes |
| Placebo BID | PLACEBO_COMPARATOR | Placebo administered twice daily (BID) to both eyes |
| Name | Type | Description |
|---|---|---|
| GLK-321 low dose BID | DRUG | Twice daily administration of low dose GLK-321 to both eyes |
| GLK-321 mid dose BID | DRUG | Twice daily administration of mid dose GLK-321 to both eyes |
| GLK-321 high dose BID | DRUG | Twice daily administration of high dose GLK-321 to both eyes |
| GLK-321 high dose QD | DRUG | Once daily administration of high dose GLK-321 to both eyes |
| Placebo BID | DRUG | Twice daily administration of placebo to both eyes |
Inclusion Criteria: * Signs of Demodex blepharitis in at least one eye * Best Spectacle Corrected Visual Acuity (BSCVA) of 20/80 Snellen or better in each eye Exclusion Criteria: * Presence of eczema or dermatitis in the ocular region of either eye * Use of lid hygiene products within 14 days of ...
GLK-321 low dose is an investigational small molecule being developed for the treatment of Demodex Blepharitis, a common eyelid condition caused by Demodex mites. It is currently in Phase 2 clinical development and has not been approved by the FDA.
The specific molecular target of GLK-321 low dose has not been disclosed. It is a small molecule being studied for its safety and efficacy in treating Demodex Blepharitis, a condition associated with eyelid inflammation and mite infestation.
GLK-321 low dose is being developed by Glaukos Corporation, a company traded on the New York Stock Exchange under the ticker symbol GKOS. The company is conducting a Phase 2 clinical trial to evaluate the drug in patients with Demodex Blepharitis.
GLK-321 low dose is in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 2 trial is actively recruiting participants in the United States.
GLK-321 low dose is being evaluated in a single Phase 2 clinical trial with the identifier NCT07400965. This randomized, double-blind, placebo-controlled study is assessing the safety and efficacy of the drug in approximately 250 subjects with Demodex Blepharitis.
Yes, GLK-321 low dose is also known as GLK-321 low dose BID. The term BID refers to the dosing frequency of twice a day, which is the regimen being studied in the ongoing Phase 2 clinical trial for Demodex Blepharitis.